Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer
Cancer Chemotherapy and Pharmacology · 2024
DOI: 10.1007/s00280-024-04670-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von In Hee Lee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology/Hematology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. Hauptthemen laut MEDLINE: Ovarian Neoplasms, BRCA1 Protein, BRCA2 Protein. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: National Research Foundation of Korea, Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI).
Themen: Onkologische Pflege
Abstract (Originalsprache)
OBJECTIVE: BRCA1/2 are integral to the DNA repair mechanism and their germline pathogenic variants (gBRCA) result in a high risk for developing breast and ovarian cancer. Patients with gBRCA mutations showed increased sensitivity to DNA cross-linking agent but might have increased treatment-related toxicities. Thus, we hypothesized that gBRCA mutation ovarian cancer patients who underwent platinum-based chemotherapy might be at higher risk of developing chemotherapy-induced hematologic toxicity. METHODS: This study enrolled 160 patients with ovarian cancer who received frontline platinum-based chemotherapy between 2011 and 2019 in Kyungpook National University Chilgok Hospital. Incidence rate and severity of chemotherapy-induced hematologic toxicity (neutropenia, anemia, thrombocytopenia) was compared for BRCA mutation and wild patients. RESULTS: 160 women, including 62 BRCA1/2 (38 BRCA1, and 25 BRCA2) mutation group, and 98 noncarriers, were analyzed. A higher frequency of G2 anemia was noted in the BRCA -mutant group (22% vs. 1%, p = 0.07). Furthermore, G3 anemia was significantly common among BRCA group (12.9% vs. 3%, p = 0.02). In the subgroup analysis according to BRCA1/2 status, BRCA1 mutated patients showed a significantly higher frequency of G1 anemia than BRCA2 (89% vs. 60%, p = 0.01). In terms of neutropenia and thrombocytopenia, BRCA mutated patients and noncarriers had similar hematologic toxicity. CONCLUSION: Germline BRCA mutations were associated with a higher frequency of G2/3 anemia in ovarian cancer patients who underwent first-line platinum-based chemotherapy. Moreover, the BRCA1 mutation appeared to be more strongly associated with the incidence of chemotherapy-induced anemia. Our findings warrant further investigation in larger, prospective studies to confirm these current findings and determine whether preventive interventions may be necessary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology/Hematology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
- Department of Oncology/Hematology, Kyungpook National University Chillgok Hospital, Daegu, Republic of Korea.
- Department of Obstetrics and Gynecology, School of Medicine, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu, 41944, Republic of Korea.
- Department of Obstetrics and Gynecology, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea.
- Department of Obstetrics and Gynecology, Kyungpook National University Hospital, Daegu, Republic of Korea.
- Department of Clinical Pathology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
ORCID-Profile: In Hee Lee, Yee Soo Chae
Förderung
- National Research Foundation of Korea
- Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI)
Zitieren
APA
Lee, I. H., Lee, S. J., Kim, J., Lee, Y. H., Chong, G. O., Kim, J. M., Lee, J., Lee, N. Y., Park, S. Y., Hong, D. G., & Chae, Y. S. (2024). Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04670-8
Vancouver
Lee IH, Lee SJ, Kim J, Lee YH, Chong GO, Kim JM, et al. Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04670-8
BibTeX
@article{Lee2024,
author = {Lee, In Hee and Lee, Soo Jung and Kim, Juhyung and Lee, Yoon Hee and Chong, Gun Oh and Kim, Jong Mi and Lee, Juhun and Lee, Nan Young and Park, Seo Young and Hong, Dea Gy and Chae, Yee Soo},
title = {Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2024},
doi = {10.1007/s00280-024-04670-8}
}
EUVIMED